COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

GlaxoSmithKline (GSK)

Status and phase: Terminated; Phase 3

Conditions: Heart Failure, Congestive and Microalbuminuria

Treatments: Drug: lisinopril; Drug: metoprolol xl; Drug: carvedilol MR

Study type: Interventional

Funder types: Industry

Identifiers

NCT00123903

COR103560

Details and patient eligibility

About

This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented history of hypertension.
• Must have been taking an ACE (angiotensin converting enzyme) inhibitor either alone or as part of an antihypertensive regimen for at least 8 weeks.
• Persistent microalbuminuria.

Exclusion criteria

• History of heart attack, stroke, congestive heart failure, arrhythmia, type 1 or uncontrolled type 2 diabetes mellitus, liver or renal disease.
• Has been taking any non-ocular beta-blockers for any indication within three months prior to Pre-screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind